Showing results (71-80 of 164) with videos related to

Sort By:
Pageof 17
Oncotarget|February 1, 2018
The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancerGong Chen, Qiong Chen, Fanxu Zeng, et al.
Therapeutic Advances in Medical Oncology|May 30, 2024
Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastasesYue Hao, Manyi Xu, Xiaohong Zeng, et al.
BMC Cancer|September 5, 2022
Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker studyYongchang Zhang, Lianxi Song, Liang Zeng, et al.
Frontiers in Oncology|November 28, 2022
PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world studyZhe Huang, Chunhua Zhou, Yi Xiong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2020
Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination TherapyYubo Wang, Nong Yang, Yongchang Zhang, et al.
Foods (Basel, Switzerland)|June 19, 2024
Preparation and Characterization of Prickly Ash Peel Oleoresin Microcapsules and Flavor Retention AnalysisZhiran Zhang, Ziyan Zhang, Xichao Li, et al.
Chinese Medical Journal Pulmonary and Critical Care Medicine|July 3, 2026
Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challengesFang Tian, Songkai Wang, Zhe Huang, et al.
JTO Clinical and Research Reports|November 6, 2024
Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK-Positive NSCLCLianxi Song, Huan Yan, Qinqin Xu, et al.
Human Pathology|May 16, 2017
Elastic staining-a rejuvenated method to reassess prognosis and serosal invasion in patients with pT3N0M0 gastric cancerGuang Lei, Haiyan Yang, Ting Hong, et al.
Communications Medicine|November 9, 2022
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancerLianxi Song, Liang Zeng, Huan Yan, et al.
Pageof 17